- Conditions
- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome
- Interventions
- triheptanoin
- Drug
- Lead sponsor
- Jerry Vockley, MD, PhD
- Other
- Eligibility
- 1 Month and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 199
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Friedreich Ataxia
- Interventions
- CTI-1601
- Drug
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Gainesville, Florida • Tampa, Florida + 5 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Roche Global Development
- Other
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more
- Conditions
- MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leigh Syndrome
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Matthew Demczko
- Other
- Eligibility
- 6 Months to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
- Interventions
- Family Centered pediatric palliative care for family caregivers of children with rare diseases.
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 12 Months to 99 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Colitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 21 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Neurodevelopmental Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 0 Months to 99 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
- Interventions
- Not listed
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Seattle, Washington
- Conditions
- Friedreich's Ataxia
- Interventions
- Placebo, EPI-743 400 mg, EPI-743 200 mg
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania
- Conditions
- Friedreich Ataxia
- Interventions
- Elamipretide
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mitochondrial Disease, Chronic Kidney Disease
- Interventions
- Probucol
- Drug
- Lead sponsor
- RiboNova Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Friedreich Ataxia
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
- Interventions
- AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
- Biological · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Friedreich Ataxia
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neurofibromatosis 1
- Interventions
- Blood draw, FACIT-F and Pain Scales
- Diagnostic Test · Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Colitis, HIV Infections
- Interventions
- Glutamic acid hydrochloride, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more
- Conditions
- Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
- Interventions
- Mutation analysis
- Genetic
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 0 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Friedreich Ataxia, Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Lexeo Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Sargramostim, Ganciclovir
- Drug
- Lead sponsor
- Schering-Plough
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more
- Conditions
- Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
- Interventions
- Seated exercise
- Behavioral
- Lead sponsor
- Burke Medical Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Friedreich Ataxia, Neuro-Degenerative Disease
- Interventions
- Not listed
- Lead sponsor
- Friedreich's Ataxia Research Alliance
- Other
- Eligibility
- 4 Years to 80 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2030
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more
- Conditions
- Down Syndrome
- Interventions
- Submaximal exercise protocol
- Other
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada